[Imatinib mesylate: a major breakthrough in the treatment of chronic myelogenous leukemia]

Med Sci (Paris). 2003 Jun-Jul;19(6-7):667-8. doi: 10.1051/medsci/20031967667.
[Article in French]
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzamides
  • Clinical Trials as Topic
  • Cytarabine / administration & dosage
  • Humans
  • Imatinib Mesylate
  • Interferon-alpha / administration & dosage
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Multicenter Studies as Topic
  • Piperazines / pharmacology*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / pharmacology*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Interferon-alpha
  • Piperazines
  • Pyrimidines
  • Cytarabine
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases